Upharmacia September 2017
CIS PHARMA NEWS
Azerbaijan——
The Head of the MoH of Belarus stated that his government is interested in establishing of joint pharmaceutical enterprise in Azerbaijan. Azerbaijani government plans to involve Azerbaijan Investment Company in the project.
——
Within the Memorandum signed between Ministry of Economy of Azerbaijan and LLC Hayat Pharm, the creation of the Association of pharmaceutical production manufacturers in Azerbaijan has been agreed.
——
The government regulated prices of 10 ths drugs registered in Azerbaijan.
Belarus——
Within the Belarusian-Indian Business Forum, the parties reached the number of cooperation agreements. The MOH of Belarus general agreement on strategic partnership with Hetero Labs Limited company. Trilateral agreement on the basic conditions between the MOH, Glorinkor Company( Belarus) and Biocon Limited( India). Same agreement between the MOH, Glorinkor Company and Cadila Healthcare Limited( India).
——
Leading Belarussian producer of pharmaceuticals Belmedpreparaty will establish experimental production of oral antitumor drugs using isolating technologies. The project envisages implementation of international GMP standards.
——
Veropharm company( part of Abbott Group) reached strategic partnership agreement with the Russian producer of pharmaceutical substances Bion. The companies will cooperate in development and production of drugs for cancer treatment, cardiovascular and central nervous system.
——
The GM of BIOCAD company, stated that in 2-3 years Russian generic market would collapse – prices for this category of drugs to drop significantly, while the generic market to cease to be the driver of the development of the pharmaceutical industry.
Kazakhstan——
Jordanian company Hikma Pharmaceuticals PLC signed investment contract with Kazakh government to build the pharmaceutical plant in Alatau industrial zone( Almaty city). The company also signed a 10-year contract with Single Distributor SK-Pharmacy on the supply of drugs on an exclusive basis.
——
According to the MOH’ s plan the regulation of Rx drugs prices will be implemented in 2018, OTC – in 2023.
Russia——
Venture Biotech Fund Primer Capital invested in the development of the drug by Gemopharm company for the treatment of multiple myeloma. The drug has already shown high efficacy in vivo.
——
BIOCAD company will build a production complex in Pushkin district in St. Petersburg. It will include the center for pre-clinical trials, as well as production of substances and finished drugs. The investments to amount RUB 3bn.
www. upharma-c. com
9